HIV has proven to be a popular target for experimental RNAi-based therapies, catching the interest of researchers from both industry and academia. Among them is Colorado State University’s Ramesh Akkina, who with some funding from the National Institute of Allergy and Infectious Diseases, is investigating the use of multiple siRNA constructs in fighting HIV.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.